| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Hillel Yaffe Medical Center |
| Information provided by: | Hillel Yaffe Medical Center |
| ClinicalTrials.gov Identifier: | NCT00397397 |
Purpose
We wish to determine the best treatment for expulsion of lower ureteral stones. Which of the three major treatment protocols is the best treatment of conservative management of ureteral stones?
| Condition | Phase |
|
Urinary Calculi |
Phase 0 |
| Drug Information available for: | Alfuzosin Alfuzosin hydrochloride |
| Study Type: | Observational |
| Study Design: | Screening, Cross-Sectional, Random Sample, Prospective Study |
| Official Title: | Comparative Study in Patients With Lower Ureteral Stones Treated With 10 MG Alfuzosin,10 MG Alfuzosin With Rowatinex, and Rowatinex Alone |
| Estimated Enrollment: | 60 |
| Study Start Date: | January 2007 |
| Estimated Study Completion Date: | March 2007 |
The study will include 60 patients with lower ureteral stones. The patients will be divided into three groups. The first group will be administered Alfuzosin (10 mg). The second group will be administered a combination of Alfuzosin (10 mg)and Rowatinex (Pinene 31%, Camphene 15%, Anetol 4%, Borneol 10%, Cineol 3%, Fenchenol 4%, Olive Oil 33%). The third group will be administered Rowatinex.
Eligibility
| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations More Information
| Study ID Numbers: | 15/2006CTIL |
| First Received: | November 8, 2006 |
| Last Updated: | November 8, 2006 |
| ClinicalTrials.gov Identifier: | NCT00397397 |
| Health Authority: | Israel: Ministry of Health |
|
|
|
|
|
|
